GlaxoSmithKline News and Research

RSS

New opportunities to save another 6.4 million lives

Vaccinating children around the world against infectious diseases has saved the lives of millions over the past several decades. Now new opportunities exist to overcome remaining challenges-and save another 6.4 million lives over the current decade, according articles in the June 2011 edition of Health Affairs. The issue was produced under the journal's grant from the Bill & Melinda Gates Foundation.

10 Jun 2011

New vaccines on the horizon

In a report published in The Lancet, researchers say there is the potential to develop 20 new or improved vaccines over the next decade. They emphasize that funding is crucial - but so is trust and confidence in vaccines. It is said that AIDS and malaria vaccines as the most important areas for research. Authors further suggest that neglected tropical diseases, such as leprosy, should also be investigated.

9 Jun 2011

The ‘decade of vaccines’ has the potential to save lives, many challenges ahead

Vaccinating children around the world against infectious diseases has saved the lives of millions over the past several decades. Now new opportunities exist to overcome remaining challenges—and save another 6.4 million lives over the current decade, according articles in the June 2011 edition of Health Affairs. The issue was produced under the journal’s grant from the Bill & Melinda Gates Foundation.

9 Jun 2011

Adjuvant combination generates memory CD8 T cells which could kill infected cells

Researchers at National Jewish Health have discovered how to prime a second arm of the immune system to potentially boost influenza vaccine effectiveness. A combination of two adjuvants, chemicals used to boost the effectiveness of some vaccines, induced CD8, or killer, T cells to join antibodies in response to influenza infection.

9 Jun 2011

GSK, Crucell to test second-generation malaria vaccine

GlaxoSmithKline and drug company Crucell, a division of Johnson & Johnson, will collaborate with the PATH Malaria Vaccine Initiative to test a second-generation malaria vaccine "within the next couple of months," Reuters reports.

8 Jun 2011

MMV honors UT Southwestern with Project of the Year for new anti-malarial drug discovery

The discovery of a potential new anti-malarial drug by a UT Southwestern Medical Center-led research team has been awarded Project of the Year by Medicines for Malaria Venture.

7 Jun 2011

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline.

7 Jun 2011

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline (GSK). This collaboration is aimed at developing a second-generation vaccine against malaria—a deadly disease that kills close to 800,000 people annually, most of them young children under age five in Africa. MVI drives the development of malaria vaccines by joining its scientific, managerial, and field expertise with companies, universities, and governments to test potential malaria vaccines and invest in those with the most promise.

6 Jun 2011

Several drug makers plan to lower prices of vaccines for GAVI purchase

Several pharmaceutical companies have pledged to lower the prices of vaccines against childhood illnesses ahead of the GAVI Alliance conference in London next week, the Guardian reports (Quinn, 6/6).

6 Jun 2011

GAVI welcomes lower pentavalent vaccine price

In the lead up to its first pledging conference on June 13, the GAVI Alliance announced today it has achieved commitments from two emerging market vaccine manufacturers to lower prices for the life-saving pentavalent vaccine, which protects against five deadly diseases. Developed country manufacturers have also offered price reductions on rotavirus and human papillomavirus, or HPV, vaccines.

5 Jun 2011

Study links loss of PTEN gene with patient's response to melanoma therapy

Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.

4 Jun 2011

GSK partners with NGOs to support health care workers in LDCs

Dow Jones/Wall Street Journal reports that GlaxoSmithKline announced Tuesday it has partnered with three non-governmental organizations to address the shortage of primary health care providers in least developed countries.

26 May 2011

Avandia withdrawal from shelves by November: FDA

The Food and Drugs Administration (FDA) has announced that in the beginning of November, the diabetes drug Avandia will no longer be sold in pharmacy shelves, due to the cardiovascular risks it’s causing its patients.

22 May 2011

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended a positive opinion for the marketing authorization of XGEVA (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.

20 May 2011

EMA CHMP issues positive opinion for marketing approval of BENLYSTA

GlaxoSmithKline and Human Genome Sciences, Inc. announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion, recommending marketing authorisation for BENLYSTA (belimumab) as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus, with a high degree of disease activity, despite standard therapy.

20 May 2011

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the initiation of a Phase 1 clinical study for ISIS-TTRRx.

19 May 2011

Two drug makers will disclose prices they charge UNICEF for vaccines

The Telegraph reports that when "UNICEF began publishing prices agreed with suppliers for a range of vaccines over the past decade, ... some companies - including GSK, Novartis, Intervax and Crucell - did not initially allow disclosure."

18 May 2011

Six-minute walking distance test effectively determines disease severity in COPD

The six-minute walking distance test, a test that measures a patient's ability to tolerate exercise and physical activity, is an effective tool for understanding disease severity in patients with chronic obstructive pulmonary disease, according to a three-year global study of patients with COPD sponsored by drug manufacturer GlaxoSmithKline.

16 May 2011

GSK, AstraZeneca and University of Manchester create new collaborative centre for inflammation research

The University of Manchester, GlaxoSmithKline and AstraZeneca announce today the creation of the Manchester Collaborative Centre for Inflammation Research, a unique collaboration to establish a world-leading translational centre for inflammatory diseases. The project starts out with an initial investment of -5M from each partner over a three year period.

From The University of Manchester 12 May 2011

GSK, NanoBio initiate two NB-001 Phase 3 trials in cold sores

NanoBio Corporation today announced the initiation of two Phase 3 multicenter trials evaluating NB-001 as a topical treatment for cold sores, a step forward in their OTC licensing agreement with GlaxoSmithKline Consumer Healthcare.

12 May 2011

GlaxoSmithKline News and Research

New opportunities to save another 6.4 million lives

New vaccines on the horizon

The ‘decade of vaccines’ has the potential to save lives, many challenges ahead

Adjuvant combination generates memory CD8 T cells which could kill infected cells

GSK, Crucell to test second-generation malaria vaccine

MMV honors UT Southwestern with Project of the Year for new anti-malarial drug discovery

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

Several drug makers plan to lower prices of vaccines for GAVI purchase

GAVI welcomes lower pentavalent vaccine price

Study links loss of PTEN gene with patient's response to melanoma therapy

GSK partners with NGOs to support health care workers in LDCs

Avandia withdrawal from shelves by November: FDA

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

EMA CHMP issues positive opinion for marketing approval of BENLYSTA

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

Two drug makers will disclose prices they charge UNICEF for vaccines

Six-minute walking distance test effectively determines disease severity in COPD

GSK, AstraZeneca and University of Manchester create new collaborative centre for inflammation research

GSK, NanoBio initiate two NB-001 Phase 3 trials in cold sores

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News